background: the adjuvanticity potential of lactobacillus casei was first suggested in an old survey. the present study was designed to investigate the efficacy of a new immunotherapy against breast cancer made by mixing an extract of heated 4t1 mammary carcinoma cell line and a heat-killed preparation of lactobacillus casei. methods: female balb/c mice (6–8 weeks old, n=40) were challenged subc...

Allergen immunotherapy can desensitize even subjects with potentially lethal allergies, but the changes induced in T cells that underpin successful immunotherapy remain poorly understood. In a cohort of peanut-allergic participants, we used allergen-specific T-cell sorting and single-cell gene expression to trace the transcriptional "roadmap" of individual CD4+ T cells throughout immunotherapy....

Sublingual immunotherapy is gaining widespread attention as a viable alternative to subcutaneous immunotherapy for the treatment of allergic rhinoconjunctivitis. In addition, sublingual immunotherapy has been studied in other allergic disorders including asthma. However, a review of published studies indicates that there are deficiencies and considerable heterogeneity in both design and data in...

background: recently, the use of granulocyte colony-stimulating factor (g-csf) has been proposed to improve pregnancy outcomes in reproductive medicine. objective: a systematic review of the current use of g-csf in patients who have difficulty conceiving and maintaining pregnancy was performed. materials and methods: two electronic databases (pubmed/ medline and scopus) were searched. study sel...

sublingual allergen immunotherapy (slit) is considered to be safer and more convenient than subcutaneus immunotherapy. slit trials with house dust mites involving patients with allergic rhinitis (ar) and asthma reported discordant results. the aim of the study was to investigate the clinical efficacy and safety of slit with dermatophagoides pteronyssinus (d.pt) extract produced in serbia and pa...

With the recent approval by the FDA of an immunotherapy for prostate cancer and another positive immunotherapy trial in melanoma, immunotherapy may finally be coming of age. So what will it take for it to become part of the standard treatment for glioblastoma? To put this question into perspective, we summarize critical background information in neuro-immunology, address immunotherapy clinical ...

Abstract Glioblastoma (GBM) and brain metastases remain largely resistant to immunotherapeutic intervention. T cell exhaustion, a differentiation state characterized by loss of function persistence, contributes this resistance. Two exhaustion subsets, progenitor (Tex_prog) terminal (Tex_term), have been identified, where only Tex_prog responsive immunotherapy. To date, the dynamics characterist...

Venom immunotherapy (VIT) is proven to be curative for insect allergy, but the mechanisms and the biomarkers associated with clinical efficacy remain elusive. We report herein the discovery of a leading candidate biomarker, osteopontin (OPN), for VIT. From cDNA microarray and clustering analyses, an increased expression of OPN was found in patients who completed 5-6 years of VIT and discontinue...

In the past two decades, immunotherapy has become a novel therapeutic modality for cancer patients. In this therapeutic modality, the immune system of patient’s body is augmented to acquire the ability of recognition and destruction of tumor/cancer cells. Cancer immunotherapy is divided into two forms: passive immunotherapy and active immunotherapy. In passive immunotherapy monoclonal antibodie...

Many investigators believe that immunotherapy will be the only selected treatment for leishmaniasis in the future. Leishmanization, vaccination or injection of stimulating mediators are among various forms of immunotherapy. In this pilot study, 5 volunteers with cutaneous leishmaniasis due to L.tropica were treated with 4 weekly intralesional injections of autologous buffy coat. Cytological and...